Abstract

Objective: Two different methods for fine needle aspiration biopsy (FNAB) of thyroid nodules (multi-pass conventional smear, MPCS; single-pass liquid-based cytology, SPLBC) were evaluated regarding the magnitude of nondiagnostic/unsatisfactory sampling ratio, and basic demographic and ultrasonographic (USG) factors to predict such outcome.Methods: One thousand FNAB patients were retrospectively assessed. Of them, 517 nodules were evaluated with the conventional smear method, and the rest were evaluated with liquid-based cytology method using the Bethesda System for Reporting Thyroid Cytopathology. FNAB technique had certain procedural differences for both pathological methods. For conventional smear, a modified "needle-only" technique with three independent passes was performed, whereas a single pass was used for liquid-based cytology. The reduction of nondiagnostic/unsatisfactory results constituted the basis of this study. Pathological results, therefore, were subgrouped under "nondiagnostic/unsatisfactory" (Category I), "benign" (Category II), and "atypia/neoplasia/malignancy" (Category III-VI).Results: Both FNAB groups were not statistically different or only slightly different regarding size (P = 0.196), echogenicity (P = 0.014), and the presence of echogenic foci (P = 0.11), therefore considered to have equal USG properties. In MPCS method, the nondiagnostic/unsatisfactory rate (i.e., Category I) was 24%. Other cytological results were as follows: Category II (67.1%), Category III-VI (8.8%). In SPLBC method, the nondiagnostic/unsatisfactory rate (i.e., Category I) was 14.5%. Other cytological results were as follows: Category II (77.6%), Category III-VI (7.8%). A significant difference was found between two sampling methods regarding pathological results (Independent samples t-test, P < 0.0001). The demographic and USG factors, considered in this study, did not offer a successful prediction of nondiagnostic/unsatisfactory outcomes.Conclusion: SPLBC has significantly lower (14.5% vs 24%) nondiagnostic rate than MPCS, and higher 77.6% vs 67.1%) Category II rate than MPCS. This may point to the possibility that MPCS method undercategorizes many benign (i.e., Category II) nodules under nondiagnostic/unsatisfactory category. The success of the former is due to the elimination of confounding material during the process. Single pass, also, increases patient comfort and compliance, and has additional advantages for the interventionalist, as it obviates the need to smear aspirates. This dramatically decreases the actual duration of the biopsy procedure and is free of interventionalist expertise for smearing.

Highlights

  • Using the constellation of USG features, a high-risk nodule may be seen on grayscale USG as a solid and markedly hypoechoic lesion with microcalcifications, a microlobulated or an irregular border, and a shape taller-than-wide. None of these features, individually or in combination, are definitive in diagnosis, and it is, critical to recognize that USG does not replace fine-needle aspiration biopsy (FNAB) evaluation [7]

  • Because of the institutional decision, department of pathology has changed its practice from conventional smears to liquid-based cytology

  • The size of the nodules that were evaluated with MPCS method was between 4 and 38 mm

Read more

Summary

Introduction

Ultrasound (USG) studies can detect thyroid nodules in up to 19%-68% of randomly selected individuals, with higher frequencies in women and the elderly [3-4]. Using the constellation of USG features, a high-risk nodule may be seen on grayscale USG as a solid and markedly hypoechoic lesion with microcalcifications, a microlobulated or an irregular border, and a shape taller-than-wide. None of these features, individually or in combination, are definitive in diagnosis, and it is, critical to recognize that USG does not replace fine-needle aspiration biopsy (FNAB) evaluation [7]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call